Cargando…

P1527: ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS

Detalles Bibliográficos
Autores principales:	Chen, Zhangjie, Zhen, Sisi, Zhao, Yuanqi, Feng, Sizhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430007/ http://dx.doi.org/10.1097/01.HS9.0000972984.92594.89

Ejemplares similares

Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases
por: Zhen, Sisi, et al.
Publicado: (2023)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

P1508: GUIDE PERSONALIZED ANTIBIOTIC STEWARDSHIP FOR PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN AML PATIENTS: BASED ON A MACHINE LEARNING MODEL
por: Feng, Xiaomeng, et al.
Publicado: (2023)

Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies
por: Yuan, Fangfang, et al.
Publicado: (2023)

P1527: NEXT GENERATION SEQUENCING IN HEREDITARY SPHEROCYTOSIS DIAGNOSIS
por: García Feria, A., et al.
Publicado: (2022)

Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options
por: Zhang, Lining, et al.
Publicado: (2023)

Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
por: Wei, Xianzhen, et al.
Publicado: (2023)

Epistolario 1512-1527 /
por: Maquiavelo, Nicolás, 1469-1527
Publicado: (1990)

Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites
por: Barron, Michelle A., et al.
Publicado: (2016)

85. The Impact of Carbapenem-Sparing Interventions on the Evolution of Resistance in Pseudomonas aeruginosa in the USA
por: Townsend, Jeffrey, et al.
Publicado: (2020)

P1511: MUCORMYCOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES: HOW TO IMPROVE THE PROGNOSIS
por: Wang, Jieru, et al.
Publicado: (2023)

Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems
por: Haenni, Marisa, et al.
Publicado: (2017)

Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
por: Zaidenstein, Ronit, et al.
Publicado: (2018)

P1512: RESISTANCE DIAGNOSTICS TOOL TO COMBAT ANTIBIOTIC RESISTANCE IN HEMATOLOGY WARDS: A MODEL-BASED EVALUATION FROM A LARGE MULTICENTER CASE–CONTROL AND COHORT STUDY
por: Feng, Xiaomeng, et al.
Publicado: (2023)

Clinical characteristics and risk factors of Aeromonas bloodstream infections in patients with hematological diseases
por: Xu, Chunhui, et al.
Publicado: (2022)

Epidemiology and mortality outcome of carbapenem- and colistin-resistant Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa bloodstream infections
por: Balkhair, A., et al.
Publicado: (2023)

Development of a Risk Prediction Model of Subsequent Bloodstream Infection After Carbapenem-Resistant Enterobacteriaceae Isolated from Perianal Swabs in Hematological Patients
por: Liu, Jia, et al.
Publicado: (2023)

Antimicrobial resistance pattern of Pseudomonas aeruginosa in clinical isolates from ICU patients
por: Antypa, E, et al.
Publicado: (2009)

Distribution of carbapenem resistant Acinetobacter Baumannii and Pseudomonas aeruginosa and ESBL-producing organisms colonization among intensive care patients
por: Santanirand, P, et al.
Publicado: (2011)

Carbapenem Susceptibility and Multidrug-Resistance in Pseudomonas aeruginosa Isolates in Egypt
por: Hashem, Hany, et al.
Publicado: (2016)

Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa
por: van der Zee, Anneke, et al.
Publicado: (2018)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study
por: Yuan, Qing, et al.
Publicado: (2023)

Screening of Antimicrobial Resistance Genes and Epidemiological Features in Hospital and Community-Associated Carbapenem-Resistant Pseudomonas aeruginosa Infections
por: Çopur Çiçek, Ayşegül, et al.
Publicado: (2021)

Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
por: Garcia, Rebeca Carvalho Lacerda, et al.
Publicado: (2023)

Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa
por: Hu, Yanyan, et al.
Publicado: (2021)

Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
por: Royo-Cebrecos, Cristina, et al.
Publicado: (2022)

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

P45 Antimicrobial activity of ruthenium-based metallo-therapeutics against Pseudomonas aeruginosa
por: Britten, Nicole S., et al.
Publicado: (2022)

Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections
por: Hart, Robert J., et al.
Publicado: (2022)

Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
por: Qin, Jie, et al.
Publicado: (2022)

Correlation Between Virulence Genotype and Fluoroquinolone Resistance in Carbapenem-Resistant Pseudomonas aeruginosa
por: Cho, Hye Hyun, et al.
Publicado: (2014)

Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa
por: Farajzadeh Sheikh, Ahmad, et al.
Publicado: (2014)

Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation
por: Rossi Gonçalves, Iara, et al.
Publicado: (2016)

Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China
por: Hu, Yan-Yan, et al.
Publicado: (2019)

Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management
por: Kim, Young Jin, et al.
Publicado: (2024)

Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa
por: Atrissi, Jad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3924nttsg0uftcmfagvk4kg2d4